As Intercept Pharmaceuticals In (ICPT) Stock Declined, Altrinsic Global Advisors Has Increased by $4.51 Million Its Stake; Sequoia Financial Advisors Has Lowered Its Cvs Health (CVS) Stake by $1.71 Million

May 15, 2018 - By wolcottdaily

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Sequoia Financial Advisors Llc decreased its stake in Cvs Health Corp (CVS) by 74.76% based on its latest 2017Q4 regulatory filing with the SEC. Sequoia Financial Advisors Llc sold 23,736 shares as the company’s stock declined 17.45% with the market. The institutional investor held 8,014 shares of the medical and nursing services company at the end of 2017Q4, valued at $581,000, down from 31,750 at the end of the previous reported quarter. Sequoia Financial Advisors Llc who had been investing in Cvs Health Corp for a number of months, seems to be less bullish one the $67.93B market cap company. The stock increased 3.74% or $2.41 during the last trading session, reaching $66.82. About 12.42 million shares traded or 37.97% up from the average. CVS Health Corporation (NYSE:CVS) has declined 22.81% since May 15, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

Altrinsic Global Advisors Llc increased its stake in Intercept Pharmaceuticals In (ICPT) by 33.44% based on its latest 2017Q4 regulatory filing with the SEC. Altrinsic Global Advisors Llc bought 77,756 shares as the company’s stock declined 3.60% with the market. The institutional investor held 310,300 shares of the health care company at the end of 2017Q4, valued at $18.13M, up from 232,544 at the end of the previous reported quarter. Altrinsic Global Advisors Llc who had been investing in Intercept Pharmaceuticals In for a number of months, seems to be bullish on the $1.82 billion market cap company. The stock increased 0.99% or $0.7 during the last trading session, reaching $71.7. About 372,846 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since May 15, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.02, from 1.33 in 2017Q3. It worsened, as 19 investors sold ICPT shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. South Dakota Council, a South Dakota-based fund reported 45,600 shares. Bb Biotech Ag, a Switzerland-based fund reported 485,719 shares. First Tru Advisors Lp reported 605,454 shares. Moreover, Fmr Ltd Llc has 0.03% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 3.77 million shares. Royal Bancorporation Of Canada stated it has 94,926 shares or 0% of all its holdings. Opus Point Prns Ltd Liability Corporation reported 3,779 shares stake. Metropolitan Life Ins Co Ny holds 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 1,335 shares. Proshare Advsr Ltd Liability Corporation reported 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). France-based Credit Agricole S A has invested 0.07% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). D E Shaw And Company accumulated 0% or 22,232 shares. Moreover, Cubist Systematic Strategies Ltd has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 3,700 shares. California State Teachers Retirement System stated it has 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Pacad Investment has 0.03% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Legal And General Public Ltd Co reported 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Teacher Retirement System Of Texas stated it has 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 74 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, April 7 by BMO Capital Markets. As per Tuesday, May 31, the company rating was maintained by Goldman Sachs. The firm has “Sell” rating by Cantor Fitzgerald given on Wednesday, July 6. The rating was maintained by JMP Securities on Tuesday, May 31 with “Market Outperform”. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Outperform” rating by Wedbush on Tuesday, April 17. The rating was maintained by Wedbush with “Buy” on Thursday, January 25. Citigroup downgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Friday, September 22 to “Neutral” rating. The company was downgraded on Wednesday, October 28 by Bank of America. Cowen & Co maintained the stock with “Buy” rating in Friday, September 22 report. The company was upgraded on Tuesday, September 22 by Vetr.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Nasdaq.com which released: “Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors” on April 24, 2018, also Seekingalpha.com with their article: “Intercept Pharmaceuticals (ICPT) Q1 2018 Results – Earnings Call Transcript” published on May 08, 2018, Streetinsider.com published: “Intercept Pharma (ICPT) Tops Q1 EPS by 20c” on May 08, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Nasdaq.com and their article: “Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance …” published on May 08, 2018 as well as Nasdaq.com‘s news article titled: “Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor …” with publication date: May 01, 2018.

Altrinsic Global Advisors Llc, which manages about $14.11B and $2.61B US Long portfolio, decreased its stake in Willis Towers Watson Pub Ltd by 189,211 shares to 935,271 shares, valued at $140.94 million in 2017Q4, according to the filing. It also reduced its holding in Kindred Healthcare Inc (NYSE:KND) by 350,000 shares in the quarter, leaving it with 287,000 shares, and cut its stake in Aon Plc (NYSE:AON).

Since February 16, 2018, it had 2 insider buys, and 1 insider sale for $713,454 activity. Shares for $1.51 million were bought by DORMAN DAVID W. 19,965 shares valued at $1.42 million were sold by Foulkes Helena on Friday, February 16.

Sequoia Financial Advisors Llc, which manages about $1.18B and $949.26 million US Long portfolio, upped its stake in Powershares Etf Tr Ii (PGX) by 63,454 shares to 384,524 shares, valued at $5.71M in 2017Q4, according to the filing. It also increased its holding in Spdr Index Shs Fds (CWI) by 8,909 shares in the quarter, for a total of 392,729 shares, and has risen its stake in Vanguard Scottsdale Fds (VONG).

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 77 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of CVS Health Corporation (NYSE:CVS) earned “Buy” rating by RBC Capital Markets on Thursday, February 8. The firm earned “Neutral” rating on Thursday, February 2 by Robert W. Baird. The firm has “Buy” rating by Bank of America given on Wednesday, April 11. The rating was maintained by Citigroup on Thursday, August 17 with “Neutral”. On Friday, September 15 the stock rating was maintained by Jefferies with “Hold”. Leerink Swann maintained the stock with “Buy” rating in Tuesday, April 10 report. As per Wednesday, January 24, the company rating was maintained by Mizuho. The firm has “Buy” rating given on Tuesday, April 17 by SunTrust. The company was maintained on Wednesday, January 17 by Robert W. Baird. Deutsche Bank maintained CVS Health Corporation (NYSE:CVS) rating on Wednesday, July 22. Deutsche Bank has “Hold” rating and $117 target.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: 247Wallst.com which released: “Alibaba, CVS, Tesla and Other Earnings to Watch For This Week” on April 29, 2018, also Seekingalpha.com with their article: “We Are Playing The CVS Hand” published on May 11, 2018, Fool.com published: “Why CVS Health Stock Gained 12% in April” on May 08, 2018. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: Seekingalpha.com and their article: “CVS Health: A Store-Level Look At The Proposed Healthcare Giant” published on April 26, 2018 as well as Fool.com‘s news article titled: “3 Top Stocks With High Dividend Yields” with publication date: May 15, 2018.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on August, 14. They expect $1.61 earnings per share, up 21.05% or $0.28 from last year’s $1.33 per share. CVS’s profit will be $1.64B for 10.38 P/E if the $1.61 EPS becomes a reality. After $1.48 actual earnings per share reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts 8.78% EPS growth.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>